TCM
NKGN

Towneley Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Towneley Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$3.78K – 49
2024
Q3 		$3.78K Hold
10,000
– – ﹤0.01% 39
2024
Q2 		$12.7K Hold
10,000
– – ﹤0.01% 39
2024
Q1 		$18.9K Buy
+10,000
New +$19.2K ﹤0.01% 47

Other funds holding NKGN

Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Towneley Capital Management's NKGN Position: Q4 2024 in Review

Towneley Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2024, closing a stake of 10,000 shares — an estimated $3.78K sold.

Towneley Capital Management first reported a position in NKGN in Q1 2024 and held it in 3 quarters. The position peaked at $18.9K in Q1 2024. 25 funds tracked by Wall St. Rank hold NKGN as of Q4 2024.

  • Towneley Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Towneley Capital Management sold 10,000 NKGen Biotech, Inc. Common Stock shares in Q4 2024, an estimated $3.78K.
  • Towneley Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2024 and held it in 3 quarters.
  • Towneley Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $18.9K in Q1 2024.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2024.

Based on Towneley Capital Management's 13F filing for Q4 2024, filed 29 Jan 2025.